Evidence map›Paper›PMID 35750322›Full record

ArticleThe journal of allergy and clinical immunology. In practice2022

The Environmental Microbiome, Allergic Disease, and Asthma.

Michael S Kelly, Supinda Bunyavanich, Wanda Phipatanakul, Peggy S Lai

Open access · greenAbstract read
In one paragraph

Article in The journal of allergy and clinical immunology. In practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Association of fever and infections with the subsequent risk of atopic diseases in children with genetic susceptibility for T1D: Results from the TEDDY cohort study.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025
    Article
  11. Review
  12. Indoor Allergen Interventions in Homes and Schools for Managing Asthma.The journal of allergy and clinical immunology. In practice · 2025
    Review
  13. Indoor bioaerosols and asthma: Overview, implications, and mitigation strategies.The Journal of allergy and clinical immunology · 2025
    Review
  14. Microbial influencers: the airway microbiome's role in asthma.The Journal of clinical investigation · 2025
    Review
  15. Article
  16. Observational
  17. A Study to Evaluate the Role of Probiotics in Allergic Rhinitis.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2024
    Article
  18. Article
  19. Article
  20. The re-emerging role of linoleic acid in paediatric asthma.European respiratory review : an official journal of the European Respiratory Society · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Michael S KellyDepartment of Internal Medicine, Massachusetts General Hospital, Boston, Mass; Harvard Medical School, Boston, Mass.
Supinda BunyavanichDivision of Allergy and Immunology, Department of Pediatrics, and Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.
Wanda PhipatanakulHarvard Medical School, Boston, Mass; Division of Allergy and Immunology, Boston Children's Hospital, Boston, Mass.
Peggy S LaiDepartment of Internal Medicine, Massachusetts General Hospital, Boston, Mass; Harvard Medical School, Boston, Mass; Division of Allergy and Immunology, Boston Children's Hospital, Boston, Mass; Division of Pulmonary and Critical Care, Massachusetts General Hospital, Boston, Mass; Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, Mass. Electronic address: PLAI@mgh.harvard.edu.
Harvard University · USIcahn School of Medicine at Mount Sinai · US

Funding

Threshold, Severity, and Immunotherapy of Peanut AllergyU19AI136053 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BUNYAVANICH, SUPINDA · 2018 to 2023
$9.1M
SICAS- Diversity SupplementU01AI110397 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI PHIPATANAKUL, WANDA · 2015 to 2020
$8.8M
Nasal biomarkers of asthmaR01AI118833 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BUNYAVANICH, SUPINDA · 2015 to 2019
$3.8M
The school microbiome and asthma morbidity in inner-city childrenR01AI144119 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LAI, PEGGY SUE · 2019 to 2023
$3.7M
Gut Microbiome Dynamics in Peanut AllergyR01AI147028 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BUNYAVANICH, SUPINDA · 2019 to 2022
$3.3M
Childhood Asthma in Urban SettingsU01AI160082 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI PAULA J BUSSE, Supinda Bunyavanich · 2021 to 2026
$2.6M
Midcareer Investigator Award: Urban School Allergen Exposures and Childhood AsthmK24AI106822 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI PHIPATANAKUL, WANDA · 2013 to 2022
$1.9M
MGH Next Generation Physician-Scientist Through Stimulating Access to Research in Residency Program (MGH-Next Gen StARR)R38HL150212 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI VYAS, JATIN M · 2020 to 2023
$1.3M
Endotoxin, the airway transcriptome, and obstructive lung diseaseK23ES023700 · NIEHS · MASSACHUSETTS GENERAL HOSPITAL · PI LAI, PEGGY SUE · 2013 to 2017
$764k
NHLBI NIH HHS R38 HL150212NIAID NIH HHS K24 AI106822NIAID NIH HHS R01 AI118833NIAID NIH HHS R01 AI144119NIAID NIH HHS R01 AI147028NIAID NIH HHS U01 AI110397NIAID NIH HHS U01 AI160082NIAID NIH HHS U19 AI136053NIEHS NIH HHS K23 ES023700
6 · The paper itself

Abstract

The environmental microbiome represents the entirety of the microbes and their metabolites that we encounter in our environments. A growing body of evidence supports the role of the environmental microbiome in risk for and severity of allergic diseases and asthma. The environmental microbiome represents a ubiquitous, lifelong exposure to non-self antigens. During the critical window between birth and 1 year of life, interactions between our early immune system and the environmental microbiome have 2 consequences: our individual microbiome is populated by environmental microbes, and our immune system is trained regarding which antigens to tolerate. During this time, a diversity of exposures appears largely protective, dramatically decreasing the risk of developing allergic diseases and asthma. As we grow older, our interactions with the environmental microbiome change. While it continues to exert influence over the composition of the human microbiome, the environmental microbiome becomes increasingly a source for antigenic stimulation and infection. The same microbial exposure protective against disease development may exacerbate disease severity. Although much has been learned about the importance of the environmental microbiome in allergic disease, much more remains to be understood about these complicated interactions between our environment, our microbiome, our immune system, and disease.

Indexed as

AsthmaHypersensitivityMicrobiotaEnvironmental ExposureHumansAllergic rhinitis (AR)AsthmaAtopic dermatitis (AD)Built environmentEnvironmentExposureFood allergy (FA)MetagenomicsMicrobiomeMicrobiota

Identifiers

PMID35750322
PMCPMC9704440
OpenAlexW4283270814

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.